Clinical evaluation of two proposed antidepressants.
D000275:Adjustment Disorders / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000480:Alkynes / Q000627:therapeutic use; D000577:Amides / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D000740:Anemia / Q000139:chemically induced; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002934:Cinnamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D005260:Female; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D008099:Liver / Q000187:drug effects; D008297:Male; D008744:Methylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009497:Neurotic Disorders / Q000188:drug therapy*; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D000480:Alkynes; D000577:Amides; D000928:Antidepressive Agents; D001549:Benzamides; D002934:Cinnamates; D003521:Cyclopropanes; D008744:Methylamines; D010919:Placebos